Nanoligent

Nanoligent is a biotech company, a spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau. Nanoligent uses state-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy. Their mission is to improve the life of patients by designing new medicines that selectively target the cells affected by disease.